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Objective: To evaluate the antibacterial activity of ten synthetic tetrahydroisoquinolines
against eight bacterial strains.
Methods: The ten tetrahydroisoquinolines synthesized via base-catalyzed Pictet–Spen-
gler cyclization were screened against a total of eight bacterial strains comprising control
and pathogenic strains by the disc diffusion and micro-dilution methods. The most active
compound was then assessed for cytotoxicity on human lymphocytes.
Results: Six of the tetrahydroisoquinolines showed broad spectrum bacteriostatic ac-
tivity. The zones of inhibition produced ranged from 7 to 23 mm for 200 mg per disc. The
presence of a lipophilic substituent at the para position of the pendant phenyl group
conferred the highest antibacterial activity. Compound 2 [1-(3,4-chlorophenyl)-6-
hydroxy-1,2,3,4-tetrahydroisoquinoline] was the most active and produced zones
ranging from 9 to 20 mm against all eight bacterial strains. Compound 2 also showed the
lowest minimum inhibitory concentration of 100 mg/mL against Escherichia coli
ATCC11775 and the lowest minimum bactericidal concentration of 800 mg/mL against
pathogenic Salmonella typhimurium. Overall, compound 2 was the most active with
bacteriostatic and bactericidal activity against three and four bacterial strains respectively.
A 50% cytotoxic concentration of 98.2 mg/mL was recorded for compound 2 indicating a
low risk of toxicity.
Conclusions: The 1-aryl-1,2,3,4-tetrahydroisoquinolines display structure-related anti-
bacterial activity and further chemical exploration of the tetrahydroisoquinoline scaffold
may yield more potent non-toxic derivatives for development into new antibacterials.1. Introduction
Bacterial infections feature among the leading causes of death
worldwide and contribute signiﬁcantly to morbidity, disability
and mortality [1]. Antibiotic chemotherapy is presently facing two
major challenges. Firstly, there is evidence of resistance to almost
all classes of antibiotics [2] and secondly, there is a great paucity
of new antibacterials approved for clinical use with only three
new classes of antibiotics approved for human use in the last
ﬁfty years [3,4]. A number of surveys of antibioticchemotherapy have revealed increasing resistance in several
pathogenic bacteria, hence the discovery of new efﬁcacious
antibiotics is urgent [5–7]. Several strategies are presently being
exploited in the discovery and development of new
antibacterials which involve chemical synthesis of novel
compounds for antibacterial screening. One such approach is
the modiﬁcation or redesign of new antibacterials from existing
antibiotics [8] and another is the synthesis of new antibiotics
based on genomics, combinatorial chemistry, high-throughput
screening and rational drug design [4]. This study focused on
the biological screening of a small library of ten recently
described tetrahydroisoquinolines (THIQs) [9].
THIQs, also called 1,2,3,4–THIQs are a class of partially
aromatic alkaloids. THIQs abound in nature and have attracted
signiﬁcant attention due to their diverse biological activities. The
THIQ skeleton is a structure frequently used in drugs interacting
with a number of biological systems [10]. The THIQ substructurean open access article under the CC BY-NC-ND
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antitumour, cardiovascular and wide ranging antimicrobial ac-
tivity including antibacterial activity [11–14]. These compounds
include the naphthylisoquinolines, benzylisoquinolines and
bisbenzylisoquinolines. The broad spectrum of biological
activities of THIQs prompted us to investigate 1-aryl-1,2,3,4-
THIQs for antibacterial activity.
2. Materials and methods
2.1. Synthesis of THIQs
The synthesis of the target compounds shown in Figure 2 has
been described in detail [9]. The corresponding hydrochlorides
were subsequently tested in vitro for antibacterial activity.
2.2. Sources and culture of test bacteria
Five pathogenic strains of bacteria were isolated from clinical
specimens in two health facilities: the South West Regional
Hospital Annex and the Solidarity Clinic, Molyko, both found in
the town of Buea, in the South West Region of Cameroon. The
strains were isolated by culturing in appropriate selective media
and identiﬁed using cultural features and API 20E biochemical
test kit (Biome´rieux, France). The strains include Escherichia coli
(E. coli), Klebsiella oxytoca (K. oxytoca), Pseudomonas aerugi-
nosa (P. aeruginosa), Salmonella typhimurium (S. typhimurium),
Sarratia odorifera (S. odorifera), and Staphylococcus aureus
(S. aureus). Three control strains E. coli (ATCC 11775),
P. aeruginosa (Boston 41501) and S. aureus (ATCC 33862) were
obtained from American Type Culture Collection (Manassas,
USA). The organisms were cultured on Muller Hinton agar
(Lioﬁlchem, Italy) in culture plates prepared according to the
manufacturer's instructions, and the cultures stored at 4 C and
sub-cultured every 48 h during the study period.
2.3. Antibacterial screen by disc diffusion
This was performed as described by Mbah et al. [15] with
some modiﬁcations mentioned below. Brieﬂy, sterile discs
(5–6 mm diameter) were prepared from Whatman ﬁlter paper.
A solution of each THIQ was prepared to give 50 mg/10 mL
in methanol. Discs containing test substance in the range 50–
200 mg per disc, gentamicin (1 mg per disc) as positive
control and negative control (using methanol) were prepared
and the solvent dried-off. The Kirby–Bauer (spread plate)
method [16] was used to assess the antibacterial activity of theFigure 1. Substructure of THIQs.THIQs. The discs were gently ﬁxed on a uniform spread of
bacterial suspension (approximately 1.5 × 108 CFUs/mL in
0.85% saline equivalent to 0.5 McFarland and incubated for
18–24 h at 37 C and the zones of inhibition measured in
millimetres. This experiment was conducted twice for each
THIQ.
2.4. Antibacterial screen by micro-dilution
A 4 mg/mL stock solution of each compound was prepared in
dimethyl sulfoxide. The minimum inhibitory concentration (MIC)
was determined in duplicate wells in a microtitre plate as described
by Mbah et al. [15], whereby the stock solution of the pure
compound was serially diluted in peptone water sugar medium
in tests wells to give ﬁnal concentration of 50 to 1 000 mg/mL
and bacterial suspension added at a ﬁnal density of
approximately 6 × 105 CFUs/mL in 0.85% sterile saline. Positive
(50 mg/mL gentamicin) and negative (bacterial cells without
drug) control wells were included and the plate incubated at
37 C for 24 h (Heraeus, Germany). The lowest concentration
well without bacterial growth (no colour change of bromothymol
blue indicator from blue to yellow) was recorded as the MIC.
The minimum bactericidal concentration (MBC) was determined
by re-incubation of a 1:10 dilution of the contents of the MIC
wells with no bacterial growth. The content of eachwell wasmixed
and 100 mL transferred into a sterile Eppendorf (1.5 mL) tube,
900 mL of the peptone medium added and mixed and the tube
capped tightly and incubated same as above. The lowest concen-
tration without bacterial growth as above was recorded as the
MBC. This experiment was conducted twice.
2.5. Cytotoxicity test
The cytotoxicity was performed for compound 2, i.e. 1-(3, 4-
chlorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline, the
most active THIQ against the eight bacterial strains in the disc
and micro-dilution experiments on human lymphocytes. The test
was conducted following reported methods with modiﬁcations
[17–19]. Ten millilitres of venous blood was collected from a
human volunteer donor by a phlebotomist in a local blood
bank into a heparinised tube; and then diluted 1:1 in Roswell
Park Memorial Institute (RPMI) 1640 medium (SIGMA,
containing 2.5 mg/mL gentamicin 1% Albumax II, 25 mmol/L
HEPES buffer, 25 mmol/L NaHCO3) and mixed by gentle
swirling [17]. The peripheral blood mononuclear cells were
then separated by density gradient centrifugation on Ficoll
at 3 900 r/min for 10 min. The layer of peripheral blood
mononuclear cells was carefully aspirated into a sterile tube
[18]. RPMI medium was added and the cells washed twice by
centrifugation at 1 800 r/min for 10 min. The cell pellet was
resuspended in 1 mL RPMI medium, thoroughly mixed, then
10 mL diluted with 10 mL of 0.4% trypan blue and counted by
light microscopy using a haemacytometer at × 400
magniﬁcation [18]. Finally, it was diluted in culture medium to
one million cells/mL. A 4 mg/mL stock solution of compound
2 was diluted serially in RPMI medium in duplicate wells in a
96–well microtitre plate giving 100 mL of test solution per
well over a range of 1.9–2 000 mg/mL. Positive control wells
containing 100 mL 0.5 mol/L sodium azide and negative
control wells of medium only were included. The cell
suspension was mixed and 100 mL (100 000 cells) added into
Figure 2. Structures of ten THIQs synthesized by base-catalyzed Pictet–Spengler cyclization.
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foil to reduce evaporation from the medium and incubated at
37 C in 5% CO2 for six days in a HERA cell 150 incubator
(Thermo electron, Germany). Then the content of each well
was mixed and 20 mL diluted 1:1 in trypan blue, and the dead
(blue-stained) and living (unstained) cells counted [19].
2.6. Data analysis
Most of the zones of inhibition produced by the test sub-
stances comprised two portions; an inner clear portion with no
visible CFUs and an outer unclear portion with scanty visible
CFUs. These two portions were measured for each zone and the
total zone equal to the sum was recorded. The average reading
for the two experiments were calculated and rounded up to the
nearest whole number. The zones of inhibition of each com-
pound was interpreted by making a relative comparison of the
total zone with the zones of inhibition of standard antibiotics
published by the Clinical and Laboratory Standards Institute [20].
Based on this criterion the antibacterial effect (diameter of zone
of inhibition) of each THIQ was then categorised as sensitive, of
intermediate sensitivity or insensitive with respect to the
bacterial species. Furthermore compounds which were active
on more than two bacterial species were classiﬁed as having
broad spectrum activity. For the cytotoxicity test, the
concentration which is cytotoxic to 50% of the cells (CC50)
was interpolated from a plot of concentration versus
percentage cell death; a CC50 value > 30 mg/mL was taken as
the cut point for lack of cytotoxicity [21].3. Results
3.1. Antibacterial activity of the THIQs
Of the ten THIQs tested, the highest total diameter of zone of
inhibition observed was 23 mm produced by compound 5, 1-(4-
Bromophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline,
against S. aureus and S. odorifera. The highest zone diameter
produced by the positive control, gentamicin, was a clear zone of
23 mm against S. typhimurium and S. odorifera (Table 1). The
total zones of inhibition produced by the THIQs ranged from 7
to 23 mm with the highest clear portion of 11 mm produced
against S. aureus by compounds 1 and 5. Nine of the ten syn-
thetic compounds produced a zone of inhibition on at least one
organism. Compound 2, 1-(3,4-chlorophenyl)-6-hydroxy-
1,2,3,4-tetrahydroisoquinoline, was the only compound which
produced a zone of inhibition against all eight bacterial strains
with the total zone ranging from 9 to 20 mm; and was also the
only compound that was active against P. aeruginosa (Boston
41501). Four THIQs (1, 2, 5 and 10) produced a zone against
more than two species. Compound 3, 1-(3-Chorophenyl)–6-
hydroxy-1, 2, 3, 4-tetrahydroisoquinoline, had no effect on
any of the organisms as neither a clear nor unclear zone was
produced.
Nine of the ten compounds showed a MIC within the range
tested (50–1 000 mg/mL) with theMIC values ranging from 100 to
1 000 mg/mL (Table 2). The lowest MIC value was 100 mg/mL
produced by compound 2 on the control (ATCC 11775) and
pathogenic strains of E. coli respectively. Only compound 4, 1-(2,
Table 1
Antibacterial activity of ten THIQs by disc diffusion method.
Bacterial strains Diameter of zone of inhibition (mm)
1 2 3 4 5 6 7 8 9 10 Gentamicin
ECa 8 (13) 10 (18) _ _ 10 (16) _ _ _ _ 8 (15) 14
EC 8 (19) 10 (14) _ _ 9 (19) _ _ _ _ 0 (16) 11
SAa 11 (16) 0 (9) _ _ 10 (22) 0 (8) _ _ _ 0 (11) 21
SA 11 (19) 0 (11) _ _ 11 (23) 0 (7) _ _ _ _ 22
ST 8 (17) 10 (14) _ 0 (7) 9 (18) _ 0 (8) 0 (9) 0 (7) 9 (15) 23
KO 9 (21) 10 (20) _ _ 9 (19) _ _ 0 (10) _ 10 (14) 20
PAa _ 0 (6) _ _ _ _ _ _ _ _ 20
SO 7 (14) 10 (18) _ _ 8 (23) _ _ _ _ 7 (12) 23
a Control strains; EC: E. coli; SA: S. aureus; ST: S. typhimurium; KO: K. oxytoca; PA: P. aeruginosa; SO: S. odorifera; ECa: E. coli (ATCC 11775);
SAa: S. aureus (ATCC 33862); PAa: P. aeruginosa (Boston 41501); –: No zone of Inhibition observed; ND: Not done; Zones are average of two
experiments at 200 mg of test substance per disc, values in parentheses are unclear zones with scanty colony forming units.
Table 2
MICs of ten THIQs (mg/mL).
Bacterial species MIC of compoundsa
1 2 3 4 5 6 7 8 9 10
E. coli (11775)a 400 100 600 >1 000 400 400 1 000 >1 000 200 600
E. coli 400 200 600 >1 000 400 400 1 000 800 400 600
S. aureus (33862)a 1 000 400 1 000 >1 000 400 600 >1 000 1 000 800 1 000
S. aureus 1 000 400 1 000 >1 000 600 800 >1 000 1 000 800 1 000
S. typhimurium 600 400 800 >1 000 600 800 >1 000 >1 000 800 1 000
K. oxytoca 600 400 600 >1 000 600 600 >1 000 >1 000 800 800
S. odorifera 600 400 600 >1 000 400 600 >1 000 1 000 800 800
a Control strains from ATCC, USA; Names and structures of compounds are shown in Figure 2.
Table 3
MBCs of ten THIQs (mg/mL).
Bacterial species MBC of compounds
1 2 3 4 5 6 7 8 9 10
E. coli (11775)a >1 000 1 000 >1 000 – >1 000 >1 000 >1 000 – >1 000 >1 000
E. coli >1 000 >1 000 >1 000 – >1 000 >1 000 >1 000 >1 000 >1 000 >1 000
S. aureus (33862)a >1 000 >1 000 >1 000 – >1 000 >1 000 – >1 000 >1 000 >1 000
S. aureus >1 000 >1 000 >1 000 – >1 000 >1 000 – >1 000 >1 000 >1 000
S. typhimurium >1 000 800 >1 000 – >1 000 >1 000 – – >1 000 >1 000
K. oxytoca >1 000 1 000 >1 000 – >1 000 >1 000 – – >1 000 >1 000
S. odorifera 1 000 1 000 >1 000 – >1 000 800 – >1 000 >1 000 >1 000
a Control strains from ATCC, USA; –: Not done; Names and structures of compounds are shown in Figure 2.
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did not produce a MIC in the range tested. Of the nine compounds
tested for MBC, three showed MBC values ranging from 800 to
1 000 mg/mL (Table 3). Again the highest number of MBC values
was recorded for compound 2 i.e. against four bacterial strains.
Overall, compound 2 demonstrated the most wide ranging
activity; it was active against all bacterial strains in the disc test
and also showed the lowest MIC values (100–400 mg/mL) and
the lowest MBC (800 mg/mL) values.
3.2. Cytotoxicity of compound 2
The concentrations which were cytotoxic to 50% and 100%
of the cells i.e. CC50 and CC100 were determined to be 98.2 mg/
mL and 500 mg/mL respectively. These values are higher than
the cut- off point for absence of cytotoxicity (CC50 > 30 mg/
mL), however they are also lower than the concentrations at
which antibacterial activity was observed which range from 100
to 1 000 mg/mL.4. Discussion
The ﬁndings of this work have revealed that the 1-aryl-1,2,3,4-
THIQs are potential broad spectrum antibacterials. Based on the
diameter of the zone of inhibition, four compounds (1, 2, 5 and
10) produced clear zones ranging from 7 to 11 mm with no
colony visible to the naked eye and a further zone with scanty
colonies ranging up to 23 mm similar to the standard antibiotic
gentamicin used as positive control in this study. Also, nine of the
ten compounds were active on at least one bacterial species. These
ﬁndings demonstrate the potential efﬁcacy of the THIQs against
pathogenic bacterial strains. On the basis of the disc diffusion test
four of the ten THIQs demonstrated antibacterial activity with
three of them demonstrating broad spectrum activity.
Based on the micro-dilution assay, compound 2 was the most
active with the lowest MIC ranging from 100 to 400 mg/mL
against all the eight bacterial strains tested, followed by com-
pound 5 (400–600 mg/mL). The activity of compounds 2 and 5
in the MIC assay conﬁrms their activity in the disc test. Though
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the bactericidal activity was weak with an MBC of 800 to
1 000 mg/mL. Overall, two compounds, 1 and 5, showed po-
tential for broad spectrum activity seen from the inhibition of
four Gram-negative and one Gram-positive bacteria in the disc
and micro-dilution (MIC) assays.
All ten compounds tested contain the same basic scaffold.
Therefore, any differences observed in their biological proﬁles
can be attributed to the nature of substituents and the substitution
patterns on the scaffold. In reviewing the data, the following four
compounds emerge as having the highest potential for antibac-
terial activity: 1, 2, 5, and 10. A common feature of these ana-
logues is the presence of a lipophilic substituent at the para
position of the pendant phenyl group. The activity of these ana-
logues sharply contrasts with that of compound 8 which contains
a smaller substituent at this same position (compare 1, 2, 5 vs 8),
suggesting that the presence of bulky lipophilic substituents at the
para position favours antibacterial activity. In contrast, substitu-
tion at the meta position of the pendant phenyl group appears to
be disfavoured, as the meta-substituted compounds display
reduced antibacterial activity (compare 1 vs 3 and 5 vs 6).
Discs of standard antibiotics contain small amounts of drug,
usually 10–30 mg with a few containing 50–300 mg hence the
amount (200 mg) which showed activity in this study falls within
the range for antibiotics in clinical use. However, in comparison
to standard antibiotics, the bacterial strains showed intermediate
sensitivity to the most active THIQs (1, 2 and 5) close to some
standard antibiotics singly and in combination such as ampicillin
(14–16mm) and doxycycline (11–13mm) on Enterobacteriaceae;
cefoperazone (16–20 mm) and trimethoprim (11–15 mm) on
S. aureus [20]. A study of 1-aryl-6,7-dimethoxy-1,2,3,4-THIQs
reported lower MICs of 3.5–20 mg/mL, against E. coli,
S. aureus and P. aeruginosa [22], suggesting that substitution of
different chemical groups in the 1,2,3,4-tetrahydroisoquinoline
parent structure signiﬁcantly affects the antibacterial activity of
the parent structure. In this respect, the ring nitrogen atom was
particularly sensitive.
The cytotoxicity test on compound 2 showed that the CC50 of
98.2 mg/mL and CC100 (500 mg/mL) were much higher than the
cut-off value (CC50 > 30 mg/mL) for lack of cytotoxicity indi-
cating that the compounds may not possess a high risk of toxicity.
High antiplasmodial activity was recorded for compound 2
[1-(3,4-chlorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline]
with IC50 = 0.395 mg/mL against Plasmodium falciparum K1
with high very selectivity for the parasite (selectivity index > 70)
relative to rat skeletal myoblast cells (L6) [9]. Therefore,
subsequent chemical modiﬁcation of this series should seek to
increase potency while reducing toxicity.
The ten THIQs studied have demonstrated moderate but
structure-related antibacterial activity. Further exploration of the
parent THIQ scaffold may lead to the discovery of more potent
and less toxic derivatives for further development into new
antibacterials.
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